A federal appeals court in New Orleans heard arguments Tuesday in a case that could do something no state law has managed: stop mifepristone, the medication used in most U.S. abortions, from being prescribed by telehealth and delivered by mail in every state, including the ones where abortion remains legal. Politico has tracked the case from its origins in Louisiana to the argument now before the Fifth Circuit.
The case is Louisiana v. FDA, and its mechanics are unusual. Louisiana is not asking a court to enforce its own abortion ban, which is already among the strictest in the country. It is asking the courts to strike down the FDA's nationwide rules that allow the drug to be prescribed remotely and dispensed through pharmacies and the mail, on the theory that those rules make its ban meaningless. A patient in Louisiana can consult a clinician in another state by video and receive pills by mail, so the state's prohibition can be bypassed from a living room.
How the case got here
The FDA first allowed telehealth prescribing of mifepristone as an emergency measure during the pandemic, then made the change permanent in January 2023. Louisiana sued, arguing the agency acted without adequate consideration of health risks and without authority to override state policy. After the Supreme Court's 2022 Dobbs decision returned abortion law to the states, Louisiana argues, the FDA's rules amount to a federal end-run around state sovereignty.
In May 2026 the Fifth Circuit ruled in Louisiana's favor, temporarily blocking telehealth and mail dispensing of mifepristone nationwide. The Supreme Court paused that ruling, so access has continued while the litigation proceeds. Tuesday's oral argument was the next full round, with the case widely expected to return to the Supreme Court for a final answer.
The posture of the federal government is a story of its own. The Trump administration is not defending the telehealth rules on the merits. It is defending the FDA only on narrow technical grounds, asking the courts to hold the case while the agency completes a new safety review of the drug. The rules' actual defenders in court are the drug's manufacturers, Danco and GenBioPro, who argue the rules rest on the FDA's scientific judgment and that unwinding them would destabilize drug regulation far beyond abortion.
The arguments, stated as each side makes them
Louisiana's position is structural. Its attorneys argue the state has a sovereign right to prohibit abortion within its borders, that the 2022 Dobbs decision returned that authority to the states, and that the FDA's telehealth rules render the prohibition inoperative. Because mailed pills cannot be intercepted at the border, the state argues, the only workable remedy is to end telehealth and mail access nationwide, even where abortion is legal. That is the feature of the case opponents find most striking: the remedy is not tailored to Louisiana at all.
The opponents' position is medical and institutional. Medical organizations including the American College of Obstetricians and Gynecologists have filed briefs arguing that mifepristone is among the most studied drugs in use, that serious adverse events occur in under one third of one percent of patients, and that telehealth care has a safety record comparable to in-person prescribing. The ACLU, which is part of the legal team defending the rules, makes the institutional argument in its strongest form: if a single state can persuade a court to override the FDA's scientific determinations, the agency's authority over every drug is weakened, and pharmaceutical innovation chills accordingly.
The case's stakes are concrete. Roughly 30 percent of U.S. abortion patients now access care through telemedicine, and the share is higher in rural areas and in states where clinics are scarce. Briefs filed on the opponents' side describe patients in every state who would lose access, including survivors of intimate partner violence, people with disabilities, and military servicemembers posted where clinics are unavailable. Louisiana's attorneys respond that the state's interest in enforcing its own law is not outweighed by convenience, and that the FDA's rules were adopted through a process that never accounted for states like theirs.
This publication takes no position on the outcome. Both sides are asking for something that would have seemed unremarkable a decade ago and now appears momentous: one asks courts to enforce a state's borders, the other asks courts to protect a federal agency's scientific judgment. The Fifth Circuit's answer, and likely the Supreme Court's after it, will determine which of those principles bends.
What to watch next
The Fifth Circuit gave no timeline for a ruling after Tuesday's argument. The Supreme Court's stay remains in effect through further proceedings, meaning pills continue to flow while the case is pending. Similar challenges are moving in Missouri and Texas, so whichever court rules first will shape the others. The safety review the administration cites as its preferred off-ramp is proceeding on its own track, and its conclusion could change the case's posture before any court has to rule on the merits.
The question underneath all of it is whether a national drug-approval system can coexist with state-by-state abortion law. That question existed before this case, and it will exist after it. Louisiana v. FDA is simply the vehicle that finally forced the courts to answer it.
Primary sources
- NPR for the case's origins, the May 2026 Fifth Circuit ruling, and the Supreme Court's stay.
- Politico for Tuesday's oral argument, the administration's posture, and the expected path back to the Supreme Court.
- American Civil Liberties Union for the amicus record and the medical safety arguments.
- The Hill for the procedural timeline and the telehealth share figures.